News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2026

2 March, 2026 Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers News Corporate Information Other Corporate Information English IR Optional
26 February, 2026 Year-End Report January-December 2025 News English Regulatory MAR Report Interim Yearend IR Optional
24 February, 2026 Egetis Therapeutics to Present at Upcoming Investor Events News Corporate Information Other Corporate Information English IR Optional
19 February, 2026 Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026 News Corporate Information Other Corporate Information English IR Optional
16 February, 2026 Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan News Corporate Information Other Corporate Information English IR Optional
4 February, 2026 FDA's rare pediatric disease priority review program extended until 2029 News Corporate Information Other Corporate Information English IR Optional
29 January, 2026 Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
16 January, 2026 Chairman of the Board of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
8 January, 2026 Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week News Corporate Information Other Corporate Information English IR Optional

2025

30 December, 2025 Change in the number of ordinary shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
19 December, 2025 Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
17 December, 2025 Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment News Corporate Information Other Corporate Information English IR Optional
10 December, 2025 Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe News Corporate Information Other Corporate Information English IR Optional
4 December, 2025 New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta News Corporate Information Other Corporate Information English IR Optional
1 December, 2025 Members of Egetis' Leadership Team acquire shares in Egetis News Corporate Information Other Corporate Information English IR Optional
27 November, 2025 Chairman of the Board of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
25 November, 2025 Interim report Q3 2025 News English Regulatory MAR Report Interim Q3 IR Optional
21 November, 2025 Invitation to Presentation of Egetis’ Third Quarter 2025 Report on November 25, 2025 News Corporate Information Presentation English IR Optional
14 November, 2025 Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
6 November, 2025 Egetis Therapeutics to Participate in Upcoming November Investor Conferences News Corporate Information Other Corporate Information English IR Optional
31 October, 2025 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
23 October, 2025 Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
15 October, 2025 Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region News Corporate Information Other Corporate Information English IR Optional
10 October, 2025 Egetis’ Nomination Committee for the 2026 Annual General Meeting News Corporate Information Nomination Committee English IR Optional
2 October, 2025 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
Next

Calendar and upcoming reports

March 11, 2026
Leerink Global Healthcare Conference (Miami, FL)

March 12, 2026
DNB Carnegie Healthcare Conference (Stockholm)

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]